Alluvi, known as BI 4744, presents a notable development in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://mnobookmarks.com/story22042605/alluvi-a-detailed-dive-into-the-drug-s-potential